SAN JOSE, Calif., Dec. 13, 2016 -- Synaptics Incorporated (NASDAQ:SYNA), the leading developer of human interface solutions, today announced the new R66452 display driver IC (DDIC) solution for enabling brilliant displays on OLED-based smartphones. The feature-rich Synaptics® ClearView™ R66452 DDIC includes the company’s best-in-class imaging processing and adds new state-of-the-art display technologies specifically designed to enhance OLED displays.
The R66452 OLED DDIC includes Synaptics’ latest OLED image processing technology, including flexible digital gamma control for smooth dimming, local-area ACL for high-contrast text, high-accuracy color enhancement, and support for high-dynamic range (HDR). With its included 90Hz refresh-rate and HDR support, R66452 is designed to offer a superior virtual reality (VR) experience on OLED smartphones. The R66452 solution integrates RAM for low-power operation and supports Full HD+ OLED panels at up to 1080x2160 (18:9) for next-generation ‘infinity display’ smartphones. The solution is available in either COF packaging for flexible displays or COG packaging for rigid displays.
“As a leader in touch and display solutions for LCD, and a leader in touch controllers for OLED, the development of this new OLED DDIC was a natural progression for Synaptics,” said Kevin Barber, senior vice president and general manager, Smart Displays Division, Synaptics. “Our longtime relationship with LCMs is a distinct advantage in that Synaptics is a trusted technology leader and providing OEMs with powerful and dependable solutions, including our new DDIC developed for next-generation OLED smartphones.”
Synaptics’ ClearView R66452 DDIC will be sampling to leading LCM’s in the coming weeks. Full production is expected in the second-half of 2017 to meet the introduction of next-generation OLED smartphones.
About Synaptics:
Synaptics is the pioneer and leader of the human interface revolution, bringing innovative and intuitive user experiences to intelligent devices. Synaptics’ broad portfolio of touch, display, and biometrics products is built on the company’s rich R&D, extensive IP and dependable supply chain capabilities. With solutions designed for mobile, PC and automotive industries, Synaptics combines ease of use, functionality and aesthetics to enable products that help make our digital lives more productive, secure and enjoyable. (NASDAQ:SYNA) www.synaptics.com.
Join Synaptics on Twitter, LinkedIn, and Facebook, or visit www.synaptics.com.
Synaptics ClearView, Synaptics and the Synaptics logo are trademarks of Synaptics in the United States and/or other countries. All other marks are the property of their respective owners.
For further information, please contact: David Hurd, Synaptics +1-408-904-2766 [email protected]


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



